Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Daily Oral Micronized Progesterone Versus the Etonogestrel Implant.

Study Design and Research Methods This study is a prospective, observational pilot study to assess the acceptability of study procedures and describe initial trends in our outcomes of interest, including endometrial stripe thickness among patients on estrogen replacement therapy after six months of either continuous oral micronized progesterone or etonogestrel implant. Participants will self-select into one of two study arms: (1) oral micronized progesterone (Prometrium), 100mg daily; or (2) etonogestrel implant (Nexplanon).

Recruitment and Enrollment Providers will identify eligible patients at routine appointments in the Children's Hospital Colorado Pediatric and Adolescent Gynecology Clinics, Endocrine Clinic, Oncofertility Clinic, and Multidisciplinary Turner Syndrome Clinic. Providers will briefly discuss the study to assess patient interest and, if the patient expresses interest, patients will be approached by a member of the study team for potential study enrollment. A member of the study team will provide an in-depth explanation of the study, answer any questions, and review the informed consent form.

If a patient decides to participate in the study, they or their legal guardian will provide a digital signature on the eConsent form (and eAssent form for participants aged 12-17). If participants would like a copy of the eConsent form, a signed copy will be emailed to the address they provide. The original consent will be stored in the secure, password protected REDCap database.

Feasibility and Timeline We will be enrolling from the following Children's Hospital Colorado-affiliated clinics: Pediatric and Adolescent Gynecology Clinic, Endocrine Clinic, Oncofertility Clinic, and Multidisciplinary Turner's Clinic. Each of these clinics routinely treats pediatric and adolescent patients requiring hormone replacement therapy. We anticipate meeting enrollment goals within one year. In a review of ICD codes for primary ovarian failure, 313 patients presented to CHCO from October 1, 2022 to October 1, 2023. Of these patients, 87 were under the age of 25 and received prescriptions for estradiol. We anticipate a 15% enrollment rate (3-4 patients per month) which translates to an 11-to-12-month enrollment period. We also anticipate that recruitment in the oral progesterone arm will be significantly higher compared to the etonogestrel implant group (\~7:1) based on clinical experience. Thus, we anticipate that recruitment may take longer in this group but will not have an enrollment timing estimate until enrollment begins. The recruitment timing of this pilot study will help inform the timeline and feasibility of a full study in the future.

Due to lack of existing literature, we do not know the optimal time to assess changes in endometrial thickness after hormone initiation in this exact study population. ACOG clinical consensus for endometrial hyperplasia is to perform histologic re-assessment of the endometrium 3-6 months after initiating progestin therapy for treatment.27 The initial clinical trials for the etonogestrel implant reference counseling patients that their bleeding pattern after 3-6 months of use will persist due to hormonal influence on the endometrium.24 Additionally, the only available study on the effect of desogstrel (the precursor hormone to etonogestrel) on endometrial protection and menstruation normalization among reproductive aged women was a 6 month randomized control trial. 25 Thus, by extrapolating this available data we will plan on a 6 month study timeline to allow enough time for endometrial changes to occur before performing a repeat ultrasound.

Data Collection The study team will conduct a base-line survey over the phone to collect relevant clinical history (e.g., ovarian failure diagnoses, previous hormone treatments etc.), stored securely in a REDCap database.

Participants will have a formal limited transabdominal pelvic ultrasound performed at two time points during the study. The first ultrasound will be performed at enrollment (baseline) on estrogen therapy alone to measure endometrial thickness prior to initiation or progesterone. Baseline ultrasounds will be ordered and scheduled for the patient at Children's Hospital Colorado at enrollment. Radiology technicians will perform the ultrasound, and a radiologist will confirm and report ultrasound results in the participant's medical record per standard of care.

After a baseline ultrasound is obtained, participants will initiate their selected progesterone therapies. Participants that select to oral progesterone will be prescribed 100mg oral micronized progesterone daily (Prometrium) for 6 months. Participants who elect for an etonogestrel implant will have a clinic appointment made in the Pediatric and Adolescent Gynecology Clinic at Children's Hospital Colorado for a Nexplanon insertion that will be performed per standard protocol. The study team will track the date of progesterone therapy initiation and schedule a second ultrasound for six-months after progesterone initiation (+/- 7 days).

The second ultrasound will be performed after 6 months of progesterone therapy. Radiology technicians-blinded to the treatment groups-will measure the endometrial lining while performing the ultrasound. The radiologist will confirm and transcribe these results in an ultrasound report in the participant's medical record. A single reviewer board certified in gynecology will confirm endometrial stripe measurements as documented by the radiologist (+/-0.2cm). If there is discordance between measurements, a third gynecologist will review the ultrasound and make the final assessment of endometrial stripe thickness to ensure consistency with measurements.

In addition to ultrasound data, the study team will collect participant self-report data. Participants will be asked to complete brief REDCap questionaries at 3- and 6 months after progesterone initiation. Questionnaires will query participants' demographic characteristics, bleeding patterns, side effects, satisfaction, and adherence to the medication. For participants in the micronized progesterone treatment arm, they will be asked to save and bring their pill bottles at the 6 month visit (a total of two pill bottles); the study team will perform pill counts or patients will upload a picture to their file of their remaining pills to assess compliance.

All data will be stored securely in the REDCap database. Participants will be compensated a total of $50 in gift cards for their participation in the study, per table below.

D. Description, Risks and Justification of Procedures and Data Collection Tools:

This study involves minimal risks to participants. There is a potential risk for loss of privacy and confidentiality. Every reasonable effort will be made to protect participant information. All data will be stored in a secure, HIPAA-compliant REDCap database. Only authorized users that have completed the appropriate trainings will be granted access to the REDCap project. Data containing patient identifiers (MRNs, service dates) will only be stored in the project database for organizational purposes and will not be exported into the final data set used for analysis. Only de-identified data will be analyzed reported in future publications.

In terms of safety of ultrasound in this patient population, pelvic ultrasounds are routinely used in the field of pediatric and adolescent gynecology and is the preferred imaging modality to identify pelvic structures. Ultrasounds themselves are safe with no ionizing radiation or risk to surrounding structures with use of ultrasound itself. A trans-abdominal approach to pelvic ultrasound is often used in young adolescent patients due to its less invasive nature. However, the gold standard for identifying pelvic structures (in particular, the endometrial lining) is use of a transvaginal ultrasound probe. The transvaginal ultrasound probe can be painful and invasive for patients, especially those who have never used tampons or are not sexually active. Therefore, we will give our patients the option for the ultrasound approach with which they are most comfortable.

Data Safety and Monitoring Plan Definitions

1. Adverse Events (AE): An AE is defined as any unfavorable medical occurrence in a human subject, temporarily associated with the subject's participation in the research study, regardless of relationship to research participation. For the purposes of this study, AEs include any events that occur because of a study procedure (i.e., transabdominal ultrasound). As this study observes the effects of a progesterone therapy selected by the participant as part of their standard of care, events that occur because of the progesterone are monitored and managed by the participant's clinical team. 2. Serious Adverse Events (SAE): SAEs are defined as any adverse event associated with a subject's participation in research that is life threatening, requires inpatient hospitalization, results in a significant disability, results in a fetal anomaly, or results in death. 3. Unanticipated Problems (UPs): UPs can include AE/SAEs that are unanticipated events related directly to participant safety or protocol deviations that put participant privacy or confidentiality at risk. These UPs are unexpected, related to participation in research, and place participants at a greater risk of harm than was previously known or recognized. 4. Protocol Deviations: A generally unplanned deviation from the protocol that is not implemented or intended as a systematic change to the study protocol. This may include enrollment of an ineligible participant and missed study visits (i.e., ultrasounds).

Assessments The study PI will collect all AEs from the date informed consent is signed until the final study visit. All AEs, SAEs, UPs, and protocol deviations will be captured on the appropriate case report form (CRF). Information collected will include event description; time of onset; assessment of seriousness, severity, relationship to study procedures, expectedness, medical care received, outcomes of event, and time of resolution.

Reporting All AEs will be reported to COMIRB in aggregate as part of the continuing review. All SAEs will be reported to COMIRB within 48 hours of the Study PI becoming aware of the event. If UPs occur during the study, they will be reported to COMIRB within 48 hours of the Study PI becoming aware of the event, further, protocol deviations that influence participant safety will be reported to COMIRB within 48 hours of PI awareness.

Monitoring The primary investigator is responsible for ensuring participants' safety throughout this study and for reporting AEs, SAEs, and UPs to COMIRB according to the timeframes listed above. The PI will review procedures for maintaining the confidentiality of the data, the quality of data collection, data management, and analyses on a semiannual basis.

Data Analysis Plan:

Endometrial lining thickness and character will be collected via formal ultrasound report by the radiologist. We will report descriptive statistics for all outcomes of interest, including continuous endometrial thickness, and categorical descriptors provided in the ultrasound report. Descriptive statistics will be presented for factors that may influence patients' estrogen levels and response to estrogen replacement including etiology of the patient's ovarian failure, current estrogen therapy formulations and doses, BMI, age, and treatment group. Due to the potential for self-selection bias, we will compare the descriptive characteristics of the baseline endometrial lining by treatment group to investigate potential differences that may exist prior to treatment that may influence the primary outcome.

We will report descriptive statistics for each of the outcomes of interest. For categorical variables, we will report count and proportion, and for continuous variables we will report mean, SD, median, and IQR. We will d

• Measure the mean endometrial thickness on estrogen replacement therapy [Срок оценки: At least 3 months on estrogen replacement therapy]